Race-based therapeutics

Area of Science:

• Integrative Medicine and Public Health
• Cardiovascular Disease Research
• Pharmacogenomics and Health Disparities

Background:

• The concept of race in medicine is biologically imprecise, as individuals of the same racial group do not necessarily share identical genetic or clinical traits.
• Despite observed variations in disease prevalence and risk factors across racial groups, race-based therapeutic strategies have yielded limited improvements in cardiovascular disease outcomes for specific populations.
• The African American population exhibits notable adverse cardiovascular disease variances and differential drug responses, highlighting a critical area for medical research.

Purpose of the Study:

• To critically evaluate the utility and limitations of race as a construct in medical research and clinical practice, particularly concerning cardiovascular disease.
• To examine the effectiveness of current race-based treatment guidelines for cardiovascular conditions in African Americans.
• To explore the potential for optimizing therapies based on physiological markers rather than race, aiming for improved patient outcomes.

Main Methods:

• Review of existing literature and guideline statements concerning race, cardiovascular disease, and pharmacogenomics.
• Analysis of epidemiological data and clinical trial outcomes related to cardiovascular risk factors and treatment responses in diverse populations.
• Exploration of emerging physiological and genetic markers for disease stratification and therapeutic individualization.

Main Results:

• Race is not a reliable proxy for physiological differences or genetic substrates, making race-based medicine inherently problematic.
• Current race-based treatment recommendations for cardiovascular disease in African Americans, particularly for hypertension and heart failure, have shown limited efficacy in altering disease progression.
• Significant variations in drug responsiveness and disease presentation exist within and across racial groups, underscoring the need for more precise therapeutic approaches.

Conclusions:

• The reliance on race in medicine is scientifically flawed and clinically inadequate for optimizing cardiovascular disease treatment.
• Future therapeutic strategies should prioritize individualized treatment plans based on objective physiological and genetic data over broad racial categorizations.
• Advancements in understanding disease mechanisms and drug responses at a molecular level will facilitate personalized medicine, ultimately benefiting all patients regardless of race or ethnicity.